Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Blood (2023) 142 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2023-186086

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Sylvain Garciaz, Amel Soua, Ilhem Rahal, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, MD, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-139918

Published: 2020

Journal Articles

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Norbert Vey, MD PhD, Marie Anne Hospital, Aude Collignon, Yves Collette, Daniel Birnbaum, Aude Charbonnier, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, Remy Castellano, Camille Montersino, Max Chaffanet, Nadine Carbuccia, Jose Adelaide, Benjamin Bouchacourt, Arnaud Guille

Blood (2018) 132 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2018-99-119263

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison

Raynier Devillier, Sabine Furst, MD, Jerome Rey, MD, Angela Granata, MD, Aude Charbonnier, MD, Samia Harbi, MD, Evelyne D'Incan, MD, Thomas Pagliardini, Catherine Faucher, MD, Claude Lemarie, Pharm.D., Colombe Saillard, MD, Faezeh Legrand, MD, Boris Calmels, Pharm.D., Bilal Mohty, MD, Valerio Maisano, MD, Christian Chabannon, MD PhD, Pierre Jean Weiller, MDPhD, Norbert Vey, Didier Blaise

Blood (2017) 130 (Supplement 1): 2038.

https://doi.org/10.1182/blood.V130.Suppl_1.2038.2038

Published: 2017

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients > 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis

Raynier Devillier, Jerome Rey, MD, Samia Harbi, MD, Aude Charbonnier, MD, Sabine Furst, MD, Colombe Saillard, MD, Angela Granata, MD, Evelyne D'Incan, MD, Catherine Faucher, MD, Claude Lemarie, Pharm.D., Faezeh Legrand, MD, Boris Calmels, Pharm.D., Valerio Maisano, MD, Bilal Mohty, MD, Christian Chabannon, MD PhD, Pierre Jean Weiller, MDPhD, Didier Blaise, Norbert Vey

Blood (2017) 130 (Supplement 1): 3327.

https://doi.org/10.1182/blood.V130.Suppl_1.3327.3327

Published: 2017

Journal Articles

The Role of Donor CMV Serostatus on Outcome after T-Cell Replete Haplo-SCT and Post-Transplant Cyclophosphamide: A Cohort Analysis on 207 Consecutive Adult Patients

Blood (2015) 126 (23): 4401.

https://doi.org/10.1182/blood.V126.23.4401.4401

Published: 2015

Journal Articles

Single Center Experience of Allogenic Hematopoietic Stem Cell Transplantation in 100 Patients with Myelodysplasia: The Impact of Graft-Versus-Host Disease

Colombe Saillard, Raynier Devillier, Sabine Furst, Jérome Rey, Angela Granata, Aude Charbonnier, Samia Harbi, Jean El Cheikh, Bilal Mohty, Catherine Faucher, Evelyne D'Incan, Luca Castagna, Christian Chabannon, Norbert Vey, Didier Blaise

Blood (2015) 126 (23): 5537.

https://doi.org/10.1182/blood.V126.23.5537.5537

Published: 2015

Journal Articles

Successfull Engraftment and Clearance of Donor Specific Antibodies after Haploidentical Related Stem Cell Transplantation for an Adult Patient with Sickle Cell Disease

Sabine FÜrst, MD, Emmanuelle Bernit, MD, Jean El Cheikh, MD, Angela Granata, MD, Samia Harbi, MD, Bilal Mohty, MD, Laurence Caymaris, Head Nurse, Claude Lemarie, MD, Boris Calmels, PharmD, PhD, Christian Chabannon, MD PhD, Christophe Picard, Djamel Mokart, MD PhD, Borje Andersson, MD PhD, Didier Blaise, MD

Blood (2014) 124 (21): 5792.

https://doi.org/10.1182/blood.V124.21.5792.5792

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation From Haploidentical Donor After Reduced Intensity Conditioning Regimen Allows Promising Disease Control In Patients With Hematological Diseases

Raynier Devillier, MD, Luca Castagna, Roberto Crocchiolo, MD PhD, Sabine Furst, MD, Samia Harbi, Jean El Cheikh, MD, Angela Granata, Bilal Mohty, MD, Catherine Faucher, MD, Didier Blaise, MD

Blood (2013) 122 (21): 2139.

https://doi.org/10.1182/blood.V122.21.2139.2139

Published: 2013

Journal Articles

Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up

Raynier Devillier, MD, Sabine Furst, MD, Roberto Crocchiolo, MD PhD, Samia Harbi, Luca Castagna, Jean El Cheikh, MD, Angela Granata, Catherine Faucher, MD, Anne Marie Stoppa, Bilal Mohty, MD, Thomas Prebet, MD, PhD, Diane Coso, MD, Jerome Rey, MD, Reda Bouabdallah, MD, Norbert Vey, MD, Didier Blaise, MD

Blood (2013) 122 (21): 3364.

https://doi.org/10.1182/blood.V122.21.3364.3364

Published: 2013

Journal Articles

Allogeneic Transplantation for Multiple Myeloma – the Swiss Experience

Sabine Gerull, MD, Yves Chalandon, MD, Markus G Manz, MD, Bilal Mohty, MD, Urs Schanz, MD, Martin Stern, MD, Georg Stussi, MD, Jakob R. Passweg, MD

Blood (2011) 118 (21): 3112.

https://doi.org/10.1182/blood.V118.21.3112.3112

Published: 2011

NARROW

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison

Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients > 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis

The Role of Donor CMV Serostatus on Outcome after T-Cell Replete Haplo-SCT and Post-Transplant Cyclophosphamide: A Cohort Analysis on 207 Consecutive Adult Patients

Single Center Experience of Allogenic Hematopoietic Stem Cell Transplantation in 100 Patients with Myelodysplasia: The Impact of Graft-Versus-Host Disease

Successfull Engraftment and Clearance of Donor Specific Antibodies after Haploidentical Related Stem Cell Transplantation for an Adult Patient with Sickle Cell Disease

Allogeneic Hematopoietic Stem Cell Transplantation From Haploidentical Donor After Reduced Intensity Conditioning Regimen Allows Promising Disease Control In Patients With Hematological Diseases

Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up

Allogeneic Transplantation for Multiple Myeloma – the Swiss Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only